FLT3 and acute myeloid leukemia: FLT3-ITD mutations are identified in 20–25% of patients with newly diagnosed AML, whereas point mutations in the tyrosine kinase domain (TKD) are identified in 5–10%, approximately half of which occur at D835 in the activation loop [21, 22].